GEO for Regulated Healthcare: What Pharma, Medtech, and Medical Devices Share When AI Answers the Question

Generative engine optimization is sold by vertical. There is a GEO playbook for SaaS, one for travel, one for legal, and a fast-growing list for healthcare. First Page Sage analyzed more than 54 healthcare GEO and AEO agencies in early 2026, ranking them in part on a proprietary AI Visibility Score that measures presence on ChatGPT, Perplexity, and Gemini. The vertical framing is good marketing. It is also hiding the one thing pharma, medtech, and medical-device teams most need to hear.

The core problem is identical across all three. A regulated claim, written once, scrutinized clause by clause, and approved against a specific cleared use, gets read by a model, compressed, and spoken back to a clinician or a patient in words nobody approved. The drug team calls the cleared use an indication. The device team calls it the instructions for use. The model does not know the difference and does not care. It paraphrases both the same way, and the same way it paraphrases a hotel review. That shared failure mode, not the vertical, is the thing to build around.

The shared problem: a paraphrase nobody cleared

Start with what is genuinely the same. In every regulated healthcare category, the asset of record is a claim that survived review because each clause was load-bearing. An answer engine does not serve that claim. It reads many sources, including yours, and writes a new sentence the user actually consumes. That sentence is generated fresh, slightly differently, per engine, per user, and re-generated when the underlying model updates. You cannot screenshot it once and call it monitored.

The demand pulling that paraphrase into existence is no longer speculative, and it is not pharma-only. More than 40 million people ask ChatGPT healthcare questions every day, and over 5 percent of all ChatGPT messages globally are about healthcare, per OpenAI. On the clinician side, the American Medical Association's 2026 survey found 81 percent of physicians now use AI professionally, more than double the 2023 rate, with summarizing medical research the single most common use. A purpose-built medical answer engine, OpenEvidence, logged one million verified-doctor clinical consultations in a single day in March 2026. None of those clinicians is reading your cleared label. They are reading the paraphrase.

And the paraphrase is not a rare edge case. A peer-reviewed-track study testing whether models stay on the safe side of FDA's clinical-decision-support line found that in time-critical emergency scenarios, 100 percent of GPT-4 and 52 percent of Llama3 responses produced device-like decision support that would not have met the non-device criteria, and 80 percent of GPT-4 responses crossed the line under a simple jailbreak. The model does not need to be attacked to overstate. It overstates by default, because fluency rewards a tighter, more confident claim, and a tighter claim is exactly what review exists to prevent.

That is the shared backbone every healthcare GEO program needs and most lack: a known-good source of truth (the cleared claim) and a continuous comparison of the machine's paraphrase against it. Visibility is necessary, but in regulated categories it is not the goal. A brand can be highly visible and badly wrong at the same time. The metric that matters is not just whether the machine mentions you. It is whether what it says matches what you were allowed to say.

What differs: indication versus IFU, drug labeling versus device advertising

Now the part the vertical playbooks get right. The compliance surface is not identical, and the differences change what you measure.

For drugs, the controlling text is the label, and the advertising rules are explicit. 21 CFR 202.1 prohibits prescription-drug advertising that is false, lacking in fair balance, or otherwise misleading, and it names using a quote or paraphrase out of context to convey a misleading idea as one of the ways an ad becomes false. That is not an analogy for what models do. It is a literal description of it. FDA enforcement makes the stakes concrete: in 2023, all five of OPDP's enforcement letters alleged the sponsor overstated efficacy by misrepresenting or drawing unsupported conclusions from clinical-trial data. In one, materials were found to imply a positive impact on all-cause mortality the underlying trial did not support, and an "observational in nature" disclaimer did not cure the misleading impression. The first OPDP untitled letter of 2024 turned on phrases as soft as "preserves quality of life" and "living well," judged to overstate a benefit the data did not establish. A paraphrase that tightens a hedge is the exact move that draws a letter.

For devices, the controlling text is the instructions for use and the cleared intended use, and the labeling net is wider than the physical label. FDA's 21 CFR Part 801 extends "adequate directions for use" beyond the label to promotional materials, websites, training documents, and software interfaces. An AI restatement of an IFU therefore falls inside regulated labeling, not outside it. FDA has been even more direct about software: its draft guidance on prescription drug use-related software treats software output that supplements or explains a sponsor's product as regulated labeling that must be truthful, non-misleading, and on-label. A feature, or a third-party model, that paraphrases your cleared use is not in a gray zone. It is in the labeling zone.

Europe sharpens the device case further. EU MDR 2017/745 Article 7 bans claims, in labelling, IFU, and advertising, that ascribe functions the device does not have, create a false impression about treatment or diagnosis, fail to inform of a likely risk, or suggest a use other than the stated intended purpose. An AI paraphrase that quietly drops a risk or implies an off-label use breaches all four categories at once. This is not a soft norm: in the Netherlands, non-compliance with the misleading-claims prohibition was implemented as a criminal offence carrying penalties up to 10 percent of the manufacturer's prior-year turnover. On the drug side, EU Directive 2001/83/EC requires every part of an advertisement to comply with the Summary of Product Characteristics and bans advertising of unauthorised products or unapproved indications. Different documents, different regulators, same mechanism: a fluent restatement that departs from the cleared text is non-compliant on its face.

So the rule of thumb is simple. The backbone is shared (a cleared claim, a machine paraphrase, a fidelity gap). The yardstick differs (label and fair balance for drugs, IFU and intended-use and risk disclosure for devices, SmPC consistency in the EU). A GEO program that measures visibility but not fidelity is solving the easy half of both.

Why medtech feels it later, and harder

Medtech is arriving at this later than pharma, and the lag is structural, not a matter of caution. The gen-AI investment is already there: McKinsey's medtech research points to broad gen-AI adoption across the industry, including in commercial and marketing functions. What is missing is the monitoring discipline pointed back at the machine.

Two forces make the device exposure sharper once it lands. First, device buying runs through procurement and committees, and that path now starts in an AI chatbot. G2's 2026 research found 51 percent of B2B software buyers begin their research with an AI chatbot more often than with Google, up from 29 percent a year earlier, and 69 percent chose a different vendor than they had initially planned based on the chatbot's guidance. A device shortlist assembled by a model that misreads your cleared indication is a lost deal you never saw bid. Second, the device claim space is bigger than a drug's: indications, performance specs, compatibility, contraindications, and a long IFU, each of which a model can compress or get subtly wrong. More surface, more drift.

This is measurable today, not someday. A worked analysis of one major device brand found 62 AI-generated mentions across 40 tracked medtech queries, a 3.16 percent citation score with every reference implicit and none directly credited, and a number-one citation rank against device competitors. Ranked first, and still nearly invisible as a credited source, with the model speaking on the brand's behalf without attribution. That is the medtech version of the pharma gap. The machine is talking about you whether or not you have given it a clean sentence to repeat.

A worked example: Varigel as a drug, then as a device

Take a fictional brand, Varigel, cleared for one narrow use with one known contraindication. Approached as a drug, the failure modes are the ones pharma teams already fear. Ask three engines what Varigel is for, and one cites the label cleanly, one adds a "commonly discussed" second use that traces to an old conference abstract the brand never promoted, and one omits the contraindication because its source summarized efficacy and skipped safety. That is off-label drift, dropped fair balance, generated unprompted and attached to your name.

Now make Varigel a device with the same narrow cleared use. The first engine restates the intended use correctly. The second describes a workflow the IFU never sanctions, implying a use outside the cleared purpose, the exact thing MDR Article 7 forbids. The third lists the performance specs but silently drops the contraindication, the precise omission Part 801 labeling rules and Article 7 are written to catch. Same model, same mechanism, different yardstick. The drug version is an OPDP problem. The device version is a labeling-and-Article-7 problem. Neither is visible to the brand without an instrument pointed at the machine.

Then ask the question almost no team in either industry can answer: across the engines your audience actually uses, how often does each of those things happen this week, and did it get better or worse after your last clearance or readout? Without continuous measurement against the cleared claim, you are guessing about a written, regulated exposure you cannot see. As GEO guidance for the sector puts it, generative engines compress the web into synthesized answers, and a brand that is not cited or summarized effectively disappears even when traditional rankings hold.

What a serious healthcare GEO program shares across verticals

Strip away the vertical labels and the program is the same three moves, run against the right yardstick.

Measure fidelity, not just visibility. Take the real questions your audience asks, run them across ChatGPT, Gemini, Perplexity, Google AI Overviews, Claude, and the medical answer engines in your space, and record two things per answer: are you mentioned, and does the mention match the cleared claim (the label for a drug, the IFU and intended use for a device). Visibility without a fidelity check is the easy half. Share of Answer matters, but in regulated categories it is paired with an accuracy verdict or it is theater.

Feed the machine the cleared sentence, in the structure it reads. Models prefer sources that are clear, structured, attributable, and consistent. Your approved indication or cleared intended use, your safety and risk language, expressed in plain machine-legible content, gives the engine a clean source to lift instead of the ambient noise. The catch is the same in both industries: the sentence you feed the machine has to be the cleared one, which means the inside of your house has to be in order before you optimize the outside.

Watch continuously and close the loop to review. A baseline taken once is a screenshot of a river. When a model updates, a competitor publishes, or a new clearance lands, the answer moves. The teams that win detect a new off-label or off-IFU drift the week it appears, trace it to a source, and route it to the people who can correct the underlying content. That requires the outside signal and the inside review system to be joined, not sitting in two tools owned by two teams.

The reason this is hard is the same across pharma, medtech, and devices: the inside and the outside have never been connected. The function that clears the claim has no view of what the machine says, and the agency that might watch the machine has no authority over the cleared claim. So drift is found late, by accident, in a forwarded screenshot.

Juncture is built for that seam in pharma. Inside, its Pre-check compares every asset against the approved label before MLR. Outside, its Answer Monitor measures Share of Answer and off-label drift across the engines your audience uses, continuously, with the join being the point: the same approved sentence you cleared inside is the sentence Answer Monitor watches for outside. Juncture's product lens is pharma, and the GEO for pharma argument and the GEO, AEO, and LLMO field guide lay out that case in full. The pattern, a cleared claim measured against its own machine paraphrase, is what every regulated healthcare category needs, and it is why GEO for medical devices and GEO for pharma are one problem wearing two yardsticks. Begin with the brand or device line you most need to see, take the baseline, and walk one drifted answer back to the cleared claim that should have been there.

Sources

1. First Page Sage, "The Top Healthcare GEO and AEO Agencies," 2026. firstpagesage.com
2. Healthcare Dive, "40 million use ChatGPT for health questions, OpenAI says," 2026. healthcaredive.com
3. American Medical Association, "More than 80% of physicians use AI professionally, AMA survey," 2026. ama-assn.org
4. PR Newswire (OpenEvidence), "1 Million Clinical Consultations in a Single Day," 2026. prnewswire.com
5. Weissman, Mankowitz and Kanter, FDA clinical-decision-support compliance study (NIH PMC), 2024. pmc.ncbi.nlm.nih.gov
6. eCFR, 21 CFR 202.1 (prescription-drug advertisements). ecfr.gov
7. Covington & Burling LLP, "2023 End-of-Year Summary of FDA Advertising and Promotion Enforcement," 2024. cov.com
8. Hyman, Phelps & McNamara, FDA Law Blog, OPDP first 2024 untitled letter, 2024. fdalawblog.com
9. eCFR, 21 CFR Part 801 (labeling; adequate directions for use). ecfr.gov
10. FDA, draft guidance on Prescription Drug Use-Related Software, 2023. fda.gov
11. Medical-Device-Regulation.eu, EU MDR 2017/745 Article 7 claims. medical-device-regulation.eu
12. Obelis, MDR Article 7 misleading-claims offence in the Netherlands, 2019. obelis.net
13. European Medicines Agency, Directive 2001/83/EC consolidated text. ema.europa.eu
14. McKinsey & Company, "Scaling gen AI in the medtech industry," 2025. mckinsey.com
15. PR Newswire (G2), "The Answer Economy," 2026. prnewswire.com
16. Wellows, "AI Search Visibility for Healthtech and Medical-Device Brands," 2025. wellows.com
17. Evertune, "Generative Engine Optimization (GEO) in Pharma," 2026. evertune.ai